SVB Wealth LLC Reduces Holdings in Agilent Technologies, Inc. (NYSE:A)

SVB Wealth LLC lowered its position in Agilent Technologies, Inc. (NYSE:A) by 5.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 66,529 shares of the medical research company’s stock after selling 3,686 shares during the period. SVB Wealth LLC’s holdings in Agilent Technologies were worth $8,624,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of A. Quantbot Technologies LP purchased a new stake in Agilent Technologies in the 1st quarter worth approximately $938,000. Cetera Investment Advisers boosted its position in Agilent Technologies by 953.3% in the 1st quarter. Cetera Investment Advisers now owns 32,694 shares of the medical research company’s stock worth $4,757,000 after purchasing an additional 29,590 shares in the last quarter. UBS Group AG boosted its position in Agilent Technologies by 84.5% in the 4th quarter. UBS Group AG now owns 325,695 shares of the medical research company’s stock worth $45,281,000 after purchasing an additional 149,159 shares in the last quarter. TD Asset Management Inc boosted its position in Agilent Technologies by 27.1% in the 4th quarter. TD Asset Management Inc now owns 1,609,420 shares of the medical research company’s stock worth $223,758,000 after purchasing an additional 343,175 shares in the last quarter. Finally, iA Global Asset Management Inc. boosted its position in Agilent Technologies by 26.2% in the 1st quarter. iA Global Asset Management Inc. now owns 21,770 shares of the medical research company’s stock worth $3,168,000 after purchasing an additional 4,523 shares in the last quarter. Hedge funds and other institutional investors own 87.42% of the company’s stock.

Agilent Technologies Stock Down 0.8 %

A stock traded down $1.16 during mid-day trading on Friday, reaching $137.20. The company had a trading volume of 1,298,388 shares, compared to its average volume of 1,734,099. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. The company has a market capitalization of $40.03 billion, a price-to-earnings ratio of 32.43, a price-to-earnings-growth ratio of 6.63 and a beta of 1.05. The firm has a fifty day simple moving average of $135.62 and a 200 day simple moving average of $139.02. Agilent Technologies, Inc. has a fifty-two week low of $96.80 and a fifty-two week high of $155.35.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter last year, the company earned $1.43 EPS. The business’s quarterly revenue was down 5.6% on a year-over-year basis. Analysts forecast that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. UBS Group upped their target price on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research note on Monday, August 26th. TD Cowen upped their target price on Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Robert W. Baird reduced their target price on Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating for the company in a research note on Thursday, May 30th. Finally, Citigroup upped their target price on Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $141.60.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now owns 24,118 shares in the company, valued at approximately $3,497,110. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the transaction, the chief executive officer now owns 24,118 shares of the company’s stock, valued at $3,497,110. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the completion of the transaction, the senior vice president now directly owns 49,486 shares in the company, valued at approximately $6,595,494.08. The disclosure for this sale can be found here. Insiders have sold 18,916 shares of company stock worth $2,557,230 in the last quarter. 0.33% of the stock is owned by insiders.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.